Publications by authors named "Fredrik Borgsten"

Claim this Profile
D
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results.
Jill Corre, Laure Vincent, Philippe Moreau, Benjamin Hebraud, Cyrille Hulin, Fredrik Borgsten

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes.
Aurore Perrot, Thierry Facon, Torben Plesner, Saad Z Usmani, Shaji Kumar, Fredrik Borgsten

Eur J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
Maria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, Kenshi Suzuki, Andrzej Jakubowiak, Fredrik Borgsten

Lancet Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on the use of subcutaneous daratumumab plus bortezomib, thalidomide, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Vania Hungria, Fernanda Lemos Moura, Abel Costa, Eduardo Flávio Oliveira Ribeiro, Paulo Soares, Fredrik Borgsten

Ann Hematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Thierry Facon, Philippe Moreau, Katja Weisel, Hartmut Goldschmidt, Saad Z Usmani, Fredrik Borgsten

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
Philippe Moreau, Thierry Facon, Saad Z Usmani, Nizar Bahlis, Noopur Raje, Fredrik Borgsten

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma.
Thierry Facon, Shaji K Kumar, Torben Plesner, Robert Z Orlowski, Philippe Moreau, Fredrik Borgsten

Future Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare resource utilisation and sickness absence in newly diagnosed multiple myeloma patients who did not undergo autologous stem cell transplantation: Trends in Sweden with the changing treatment landscape.
Fredrik Borgsten, Xenia Gatopoulou, Marta Pisini, Magnus Tambour, Frida Schain

Eur J Haematol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-word data on autologous stem cell transplantation in older patients with multiple myeloma.
Frida Schain, Annica Dominicus, Fredrik Borgsten, Marlene Mozart, Magnus Björkholm

Ann Hematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis